Agents and combinations successfully targeting mutant-KRas containing tumor cells, in an epithelial or mesenchymal cell context, would have a marked impact in the treatment of NSCLC and particularly pancreas cancer where trans-differentiation is a frequent event (22). Here, KRAS is linked to non-small cell lung carcinoma.